FDA Approves New Treatments for Psoriatic Arthritis, Depression

The FDA Sept. 30 approved new treatments for adults with psoriatic arthritis and major depressive disorder (MDD), saying “it is important to have a variety of treatment options.” The agency approved UCB’s Cimzia (certolizumab) for the treatment of active psoriatic arthritis, a chronic, inflammatory condition affecting the joints and tendons. Takeda and Lundbeck’s MDD drug Brintellix (vortioxetine) was also granted approval.
Washington Drug Letter